FOR THE TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)

TREMFYA^® is the only* selective IL-23i designed to neutralize inflammation at its cellular source¹

*”Only” based on approved IL-23 inhibitors for active PsA as of April 2024.

Findings are limited to in vitro studies that demonstrated guselkumab’s binding to CD64 in an inflammatory monocyte model. The clinical significance of the findings is not known.

Learn about the TREMFYA^® molecular structure with Dr. Gordon Lam

Dr. Gordon Lam is a paid consultant for Janssen and must present information in accordance with FDA
guidelines. Learn more about Dr. Lam

TREMFYA^® is structurally different¹

Consistent with the IL-23 class, TREMFYA^® is a monoclonal antibody that selectively binds to the p19 subunit of interleukin 23 (IL-23) and inhibits its interaction with the IL-23 receptor.²

TREMFYA^® is structurally different in the Fc region from other selective IL-23 inhibitors approved in active PsA. Only TREMFYA^® is fully human and able to bind to CD64 with its Fc region at the source of IL-23 production.*

Differences in clinical pharmacology cannot be used to establish differences in efficacy or safety.

CD64=FcyRI; Fc=fragment, crystallizable; WT=Wild-type.

TREMFYA^® is the only selective, dual-acting^† IL-23i

The only IL-23i designed to neutralize inflammation at its cellular source^†

^†“Dual acting” refers to:

• Blocking IL-23 by binding to p19 subunit of IL-23
• Binding to CD64 present on cells producing IL-23

The clinical significance of these findings is unknown. Findings for dual acting are limited to in vitro studies that demonstrated guselkumab’s binding to CD64 in an inflammatory monocyte model.

CD64=FcyRI; Fc=Fragment crystallizable region.

*”Only” based on approved IL-23 inhibitors for active PsA as of April 2024.

cp-440340v1